We have a strong foundation in place and look forward to the upcoming PDUFA date for Reblozyl in first line ESA-naive MDS patients on the COMMANDS data, which will further accelerate growth of the ban upon anticipated approval at the end of next month. Moving on to our transformative cell therapy products of Abecma and Breyanzi, we continue to make progress at expanding capacity which has enabled robust sales of $232 million, growing 81% versus prior year, driven by strong demand. Abecma booked sales of a $132 million globally, growing 48% versus last year, primarily due to demand and an increase in manufacturing capacity. We expect third quarter revenues to be lower than second quarter revenues due in part to planned manufacturing maintenance in June with growth expected in the fourth quarter.